Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer.
about
Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic TMPRSS2:ERG fusion status.Androgen regulation of the TMPRSS2 gene and the effect of a SNP in an androgen response elementThe role of TMPRSS2:ERG in molecular stratification of PCa and its association with tumor aggressiveness: a study in Brazilian patients.Genomic rearrangements in prostate cancer.Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients.Serum Autoantibodies in Chronic Prostate Inflammation in Prostate Cancer Patients.Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.Defining order and timing of mutations during cancer progression: the TO-DAG probabilistic graphical modelPutative Prostate Cancer Risk SNP in an Androgen Receptor-Binding Site of the Melanophilin Gene Illustrates Enrichment of Risk SNPs in Androgen Receptor Target Sites.The genomic landscape of prostate cancerInherited determinants of early recurrent somatic mutations in prostate cancer.Prostate cancer in Jordanian-Arab population: ERG status and relationship with clinicopathologic characteristics.Molecular archeology: unearthing androgen-induced structural rearrangements in prostate cancer genomes.Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.TMPRSS2-ERG gene fusion in Turkish patients with localized prostate cancer: results of radical prostatectomy specimensAspirin and NSAID use in association with molecular subtypes of prostate cancer defined by TMPRSS2:ERG fusion status.ERG oncoprotein expression in prostate carcinoma patients of different ethnicities.Immunohistochemical staining of ERG and SOX9 as potential biomarkers of docetaxel response in patients with metastatic castration-resistant prostate cancer.Expression of ERG Protein and TMRPSS2-ERG Fusion in Prostatic Carcinoma in Egyptian Patients.[Novel preclinical models and biomarkers for prostate cancer].Ethnicity and ERG frequency in prostate cancer.SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG.The Use of Biomarkers in Prostate Cancer Screening and Treatment.The Role of Immunohistochemical Analysis as a Tool for the Diagnosis, Prognostic Evaluation and Treatment of Prostate Cancer: A Systematic Review of the LiteraturePredictive significance of - fusion in prostate cancer: a meta-analysis
P2860
Q33640983-98E46948-50D2-4BFC-A0D0-29ADC53ACD87Q33663401-1C3C078E-8D8C-4678-9549-FC464923718CQ33876961-C8362613-5EF2-480A-A3EE-A39E2169A9D9Q34722101-AB831CFD-3F51-47BC-94DF-B1CC94A0A5A8Q35690915-FDA60D19-DE18-4DF8-ADD8-A856C161E733Q35919544-E036B5CE-634E-4B74-8075-EC45EBE79DA9Q36035812-2C8AF127-8454-45C2-A354-4F508C7526C9Q36149716-FE1C4C7F-AC72-4034-B52B-75197E8085ACQ36469793-B06063B3-0E7E-4200-8B1A-6206193038CEQ38109474-9D6AB993-A506-4593-BB10-022BDBD7A654Q38701501-B024AF81-0ABB-4E63-8F39-FDEA9D978DADQ38760532-9D91D5FF-3093-4000-A787-6549F738C1E3Q39947327-B5D80DF9-2D63-4DD1-A57E-19B8DE40F1FBQ40281409-542B0158-E279-4D93-BF77-080CFE689845Q41052383-358CC94C-B4DC-4B47-9AC0-42DA2172185FQ41184528-2B3006EF-CF89-47F4-8085-71C755869362Q41733293-18E3F0B7-E84C-4204-BE8B-6BBB3BDF5265Q41839242-731BB4E8-25E5-497A-BAD5-C1D6784B4312Q42287150-A843FD87-4BD0-46E8-896D-53BF72F46007Q44582971-EFE0C1A3-69E9-4B31-A1E2-19DB7155BDECQ46504038-C8222D39-D081-453F-BE6E-7BB9B3204F4CQ47333876-4158E2A3-B09C-442F-ABB4-B2B5079EF64CQ52689045-05562287-6746-43C6-B61A-BF4F31BF24AAQ57073785-A4FE2D6F-C367-4044-A360-E98CD690BCE2Q59136276-569790C3-F94C-4C25-8236-9A3DECF73306
P2860
Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Distinct ERG rearrangement pre ...... nd in low PSA prostate cancer.
@en
type
label
Distinct ERG rearrangement pre ...... nd in low PSA prostate cancer.
@en
prefLabel
Distinct ERG rearrangement pre ...... nd in low PSA prostate cancer.
@en
P2093
P2860
P50
P356
P1476
Distinct ERG rearrangement pre ...... and in low PSA prostate cancer
@en
P2093
G Schaefer
J-M Mosquera
M Ladurner-Rennau
W Horninger
P2860
P2888
P304
P356
10.1038/PCAN.2013.4
P577
2013-02-05T00:00:00Z